{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:21:45Z","timestamp":1771687305010,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40122-024-00586-6","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T07:02:00Z","timestamp":1711609320000},"page":"557-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Samuel","family":"D\u00edaz Insa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Viguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Medrano Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Calle de Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Porta-Etessam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ciudad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Diaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Roncero Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2675-0945","authenticated-orcid":false,"given":"Mercedes","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"1","key":"586_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia"},{"issue":"10283","key":"586_CR2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485\u201395.","journal-title":"Lancet"},{"issue":"2","key":"586_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19(2):109\u201317.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"586_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34.","journal-title":"J Headache Pain"},{"issue":"4","key":"586_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/0333102410382794","volume":"31","author":"J Mat\u00edas-Guiu","year":"2011","unstructured":"Mat\u00edas-Guiu J, Porta-Etessam J, Mateos V, et al. One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia. 2011;31(4):463\u201370.","journal-title":"Cephalalgia"},{"key":"586_CR6","unstructured":"NICE. Nacional Institute for Health and Care Excellence. Management of migraine (with or without aura). NICE. 2018. https:\/\/pathways.nice.org.uk\/pathways\/headaches. Accessed 29 Jan 2024."},{"key":"586_CR7","unstructured":"Santos Lasaosa S, Rosich PP, Nieto RB, Latorre Gonz\u00e1lez G, Gonz\u00e1lez Oria C. Manual de Pr\u00e1ctica Cl\u00ednica en Cefaleas. Recomendaciones diagn\u00f3stico terap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda en 2020. https:\/\/www.sen.es\/pdf\/2020\/ManualCefaleas2020.pdf. Accessed 29 Jan 2024."},{"issue":"11","key":"586_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1212\/WNL.0b013e3182a43b32","volume":"81","author":"WF Stewart","year":"2013","unstructured":"Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. Neurology. 2013;81(11):948\u201355.","journal-title":"Neurology"},{"key":"586_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020;11:417.","journal-title":"Front Neurol"},{"issue":"1","key":"586_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garc\u00eda-Azor\u00edn D, N\u00fa\u00f1ez M, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022;23(1):78.","journal-title":"J Headache Pain"},{"issue":"10","key":"586_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","volume":"176","author":"J Schoenen","year":"2020","unstructured":"Schoenen J, Manise M, Nonis R, G\u00e9rard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788\u2013803.","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"586_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Majl\u00e1th Z, Szok D, Cs\u00e1ti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667\u201381.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"586_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099\u2013142.","journal-title":"Physiol Rev"},{"key":"586_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pnp.544","volume":"23","author":"R Krishnaswamy","year":"2019","unstructured":"Krishnaswamy R, Malik BH, Khan S, et al. Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics. Prog Neurol Psychiatry. 2019;23:26\u201333.","journal-title":"Prog Neurol Psychiatry"},{"issue":"1","key":"586_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67.","journal-title":"J Headache Pain"},{"key":"586_CR16","unstructured":"EMA. EMA. Emgality Summary of Product Characteristics| European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emgality-epar-product-information_en.pdf. Accessed 29 Jan 2024."},{"key":"586_CR17","unstructured":"AEMPS. Informe de Posicionamiento Terap\u00e9utico de galcanezumab (Emgality\u00ae) en la profilaxis de migra\u00f1a. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-galcanezumab-Emgality.pdf?x17133. Accessed 29 Jan 2024."},{"issue":"24","key":"586_CR18","doi-asserted-by":"publisher","first-page":"E2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):E2211\u201321.","journal-title":"Neurology"},{"issue":"9","key":"586_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"8","key":"586_CR20","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase\u00a03 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354.","journal-title":"Cephalalgia"},{"issue":"5","key":"586_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s12325-020-01319-9","volume":"37","author":"V Martin","year":"2020","unstructured":"Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020;37(5):2034\u201349.","journal-title":"Adv Ther"},{"issue":"10","key":"586_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03b trial. Lancet Neurol. 2020;19(10):814\u201325.","journal-title":"Lancet Neurol"},{"key":"586_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31:357\u201367.","journal-title":"Cephalalgia"},{"key":"586_CR24","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56:S20\u20138.","journal-title":"Neurology"},{"key":"586_CR25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB. Determining thresholds for meaningful change for the Headache Impact Test (HIT-6) total and item-specific scores in chronic migraine. Headache. 2020;60:2003\u201313.","journal-title":"Headache"},{"issue":"1","key":"586_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s10194-023-01690-2","volume":"24","author":"V Obach","year":"2023","unstructured":"Obach V, Velasco F, Alvarez ER. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1\u00a0year follow-up from the Galca-Only registry. J Headache Pain. 2023;24(1):157","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"586_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, et al. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci. 2020;41(Suppl 2):487\u20138.","journal-title":"Neurol Sci"},{"key":"586_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence. 2022;16:821\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"15 Suppl","key":"586_CR29","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1212\/WNL.96.15_supplement.2145","volume":"96","author":"K Tangirala","year":"2021","unstructured":"Tangirala K, Cohen JM, Pandya S, Krasenbaum LJ, Thompson SF, Chen C-C. Real-world adherence, persistence, switching, and reinitiation by quarterly and monthly dosing regimen in patients prescribed AJOVY in US physician practices (2145). Neurology. 2021;96(15 Suppl):2145.","journal-title":"Neurology"},{"issue":"5","key":"586_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"key":"586_CR31","unstructured":"Zunzunegui P, Alvarez R, Riesco N, et al. Galcanezumab es un tratamiento efectivo en pacientes con migra\u00f1a cr\u00f3nica y fibromialgia. LXXIV Reuni\u00f3n Annual de la SEN 2022."},{"issue":"1","key":"586_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","volume":"23","author":"M Silvestro","year":"2022","unstructured":"Silvestro M, Tessitore A, Orologio I, et al. Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain. 2022;23(1):69.","journal-title":"J Headache Pain"},{"issue":"8","key":"586_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42(8):705\u201314.","journal-title":"Cephalalgia"},{"issue":"6","key":"586_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol Scand. 2022;145(6):669\u201375.","journal-title":"Acta Neurol Scand"},{"key":"586_CR35","doi-asserted-by":"crossref","unstructured":"Vaghi G, Vito DI, Guaschino R, Allena E, Tassorelli M, Sances C. Real life experience of one year treatment with galcanezumab in chronic migraine with and without medication overuse headache. J Neurol Sci. 2021;429.","DOI":"10.1016\/j.jns.2021.119292"},{"issue":"2","key":"586_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2020;60(2):348\u201359.","journal-title":"Headache"},{"issue":"1","key":"586_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s10194-021-01230-w","volume":"22","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021;22(1):15.","journal-title":"J Headache Pain"},{"issue":"4","key":"586_CR38","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N, et al. GARLIT Study Group. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022;29(4):1198\u2013208.","journal-title":"Eur J Neurol"},{"issue":"11","key":"586_CR39","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. Adv Ther. 2021;38(11):5465\u201383.","journal-title":"Adv Ther"},{"issue":"5","key":"586_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","volume":"38","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731\u201342.","journal-title":"Curr Med Res Opin"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:26:44Z","timestamp":1716391604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00586-6","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vicente Medrano, Jes\u00fas Porta-Etessam and Ana Roncero declare that they have no competing interests; Javier Viguera, has received speaker honoraria from Lilly, Lundbeck, Novartis and Teva; Samuel D\u00edaz-Insa has received speaker honoraria from Fundaci\u00f3 Universitat-Empresa, Abbie-Allergan, Kern Pharma, Lilly, Lundbeck, Novartis, Organon and Teva and participating in advisory boards from Kern Pharma, Lilly, Lunbeck, Novartis and Teva; \u00c1ngel Lu\u00eds Guerrero has received honoraria for lectures or advisory boards from Allergan-Abbvie, Exeltis, Lilly, Novartis, Lundbeck, Pfizer and Teva, and research support from Abbvie-Allergan, Lilly and Teva; Carlos Calle de Miguel has received speaker honoraria from Asociaci\u00f3n Madrile\u00f1a de Neurolog\u00eda and has received payments to support travel to meetings from Lilly; and Antonio Ciudad, Silvia D\u00edaz-Cerezo and Mercedes N\u00fa\u00f1ez are full time employees at Lilly and minor owners of Lilly shares.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the Good Pharmacoepidemiology Practices (GPPs) guidelines of the International Society for Pharmacoepidemiology, and local rules and regulations. The study protocol was sent to the Spanish Health Authorities for classification and was subsequently evaluated and approved by a central ethics committee (Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n con Medicamentos del \u00c1rea de Salud Valladolid Este, Spain). This approval was notified to all the ethics comittees of the participant centers which agreed with the conduction of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}